SynAct Pharma ABOMXSTO: SYNACT

SynAct Pharma: CEO has acquired shares in the company

· Issued by SynAct Pharma AB

Summary by 6ix AI

Jeppe Øvlesen, CEO of SynAct Pharma AB, has acquired 20,313 shares in the company. SynAct is a clinical-stage biotechnology company developing treatments for inflammation that aim to help the body resolve it, an approach it calls "pro-resolution".

Key details

  • The shares were bought on Nasdaq Stockholm, where SynAct is listed.

6ix AI wrote this summary from the release below and checked it against the release.

SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution", today announced that its CEO, Jeppe Øvlesen, has acquired 20,313 shares in the company.

"SynAct has an exciting future ahead, and I am very confident in the potential we are building. My investment reflects my strong belief in the company's potential and my long-term commitment to SynAct," said CEO Jeppe Øvlesen.

The shares were acquired on Nasdaq Stockholm.

For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

Investors and Media
Mary-Ann Chang, Cohesion Bureau
E-mail: synactpharma@cohesionbureau.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical-stage biotechnology company pioneering pro-resolution therapies for inflammation through selective activation of the melanocortin system. Its lead asset, resomelagon (AP1189), is a once-daily oral, first-in-class biased agonist of the MC1 and MC3 melanocortin receptors, that has completed Phase 2b development in rheumatoid arthritis, and is in Phase 2 development as host-directed therapy to treat inflammation caused by infections, including respiratory viral infection and dengue. Behind resomelagon, SynAct is building a broad portfolio of oral small molecule and injectable peptide melanocortin agonists designed to induce anti-inflammatory pro-resolution activity, helping patients restore immune balance. For more information, please visit www.synactpharma.com.

Attachments
SynAct Pharma CEO has acquired shares in the company

SynAct Pharma AB on 6ix

Earlier from SynAct Pharma

Later from SynAct Pharma

All SynAct Pharma news releases